Navigation Links
AssureRx Adds VP of Sales and Marketing

Personalized medicine company prepares for commercial launch of first


CINCINNATI, April 28 /PRNewswire/ -- AssureRx, a personalized medicine company, announced that Al Lucas has joined the Company as vice president of sales and marketing. He will be responsible for developing the marketing plan and initial launch strategy, building the sales force, and leading the commercial introduction of the Company's first product. Lucas is an experienced pharmaceutical sales and marketing leader with more than 20 years of experience at companies such as Novartis, Pharmacia, and The Upjohn Company. In his various roles with those companies, he has participated in more than 15 successful product launches, including the highly successful Zyvox (linezolid). Additionally, he played roles in the planning, hiring and training of multiple sales forces.

"I was very excited about the opportunity to join AssureRx in this early stage," said Lucas. "The personalized medicine movement will change the way medicine is practiced, and AssureRx has positioned itself to become the market leader within the largest potential segment, the neuropsychiatric field. The Company has solid relationships with the thought leaders in psychopharmacogenetic research, which supports the development of our products. We will leverage this cutting-edge technology to bring tools to the marketplace which will help physicians provide individualized and highly-specific care to each patient," Lucas continued. "These are the hallmarks of personalized medicine."

Mark Byrne, AssureRx CEO added, "We are extremely pleased that Al has joined AssureRx. He brings a demonstrated track record of successful new product introductions and is experienced in the neuro-pscyh market segment. The addition of Al will accelerate our commercial introduction."

About AssureRx

AssureRx, LLC, is a personalized medicine company dedicated to helping physicians determine the right drug at the right dose for individual patients suffering from a range of medical conditions. The company was founded in June 2006 to license and commercialize the industry-leading personalized medicine technology of Cincinnati Children's Hospital and the Mayo Clinic. The proprietary technology is based on pharmacogenetics -- the study of the genetic factors that influence an individual's response to drug treatments -- as well as evidence-based medicine and clinical pharmacology. The result is a trusted guide that helps doctors select the right drug at the right dose right now.

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AssureRx Closes Round of Funding to Commercialize Pharmacogenetic Test
2. Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company
3. Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer
4. Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%.
5. VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales
6. Developing Sales Leaders: Benchmarks Reveal Tactics that Will Propel Your Business
7. Sumitomo Corporation of America Named Exclusive Distribution and Sales Agent for Chiral Quest
8. Dilon Technologies Closes First Quarter With Record Sales
9. Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
10. Sangui BioTech International, Inc., Reports Sales Increase, Continued Losses
11. Spectros Corporation Reports 2007 Year-Over-Year Sales Rise 36%
Post Your Comments:
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and ... San Diego Rotary Club. The event entitled “Stem Cells and Their ... 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter ...
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
(Date:10/10/2017)... ... 2017 , ... The Pittcon Program Committee is pleased to ... who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each award ... conference and exposition for laboratory science, which will be held February 26-March 1, ...
(Date:10/9/2017)... , ... October 09, 2017 , ... The award-winning American ... broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , ... faced with the challenge of how to continue to feed a growing nation. At ...
Breaking Biology Technology:
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
Breaking Biology News(10 mins):